EUVIMEDEUVIMED entdecken
Kohortenstudie

Identifying subgroups of ypN1 breast cancer patients who may exempt from axillary lymph node dissection after neoadjuvant chemotherapy: insights from a large cohort study

Peinan Liu, Dandan Liu, Changying Zhao, Yumeng Wei, Xingyu Liu, Hanxiao Cui, Xuyan Zhao, Lidan Chang, Shuai Lin, Hao Wu, Xiaobin Ma, Huafeng Kang und 1 weitere

Breast Cancer · 2025

DOI: 10.1007/s12282-024-01663-6 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Breast Cancer, 2025. Verfasst von Peinan Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Lymph Node Excision. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Xi'an Jiaotong University, Xi’an Jiaotong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In patients with breast cancer staged ypN1 after neoadjuvant chemotherapy (NAC), there is limited evidence-based guidance regarding exemption from axillary lymph node dissection (ALND). METHODS: This study analyzed ypN1 breast cancer patients post-NAC from the Surveillance, Epidemiology, and End Results databases. Patients were categorized into the breast-conserving surgery (BCS) group and the total mastectomy (TM) group, and further divided by the number of positive lymph nodes (LNs). The effects of three axillary management strategies, ALND, sentinel lymph node biopsy combined with radiotherapy (SLNB + RT), and ALND + RT were compared. The overall survival (OS) and breast cancer-specific survival (BCSS) of all subgroups and their independent risk factors were analyzed. Independent prognostic factors selected from multivariate Cox analysis were utilized to create nomograms for predicting OS and BCSS. RESULTS: A total of 3641 patients were involved, with 1331 in the BCS group and 2310 in the TM group. In the TM group, patients with 3 residual positive LNs exhibited significant improvements in OS and BCSS when treated with ALND + RT. For patients with 1 or 2 residual positive LNs in the TM group and all BCS patients, no significant survival differences in survival outcomes were observed among the three axillary management methods. The accuracy of the nomograms was validated via calibration curves, receiver operating characteristic curves, and decision curve analysis curves. CONCLUSION: For TM group patients with 3 residual positive LNs after NAC, ALND + RT is recommended. For other subgroups of ypN1 patients, SLNB + RT can be considered an alternative to ALND. The nomogram developed to predict OS and BCSS in ypN1 breast cancer patients demonstrated excellent predictive ability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLymph Node ExcisionHumansFemaleNeoadjuvant TherapyMiddle AgedAxillaSentinel Lymph Node BiopsyAdultNomogramsAgedPrognosisNeoplasm StagingMastectomy, SegmentalMastectomyLymph NodesSEER ProgramLymphatic MetastasisRetrospective StudiesChemotherapy, Adjuvant

Stichwörter der Autor:innen

Axillary lymph node dissectionBreast cancerNeoadjuvant chemotherapySentinel lymph node biopsy

Autor:innen und Institutionen

  • The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
  • Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
  • School of Basic Medical Sciences, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.
  • The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. kanghuafeng1973@126.com.
  • The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. wmeng0308@126.com.

Förderung

  • Xi'an Jiaotong University
  • Xi’an Jiaotong University

Zitieren

APA

Liu, P., Liu, D., Zhao, C., Wei, Y., Liu, X., Cui, H., Zhao, X., Chang, L., Lin, S., Wu, H., Ma, X., Kang, H., & Wang, M. (2025). Identifying subgroups of ypN1 breast cancer patients who may exempt from axillary lymph node dissection after neoadjuvant chemotherapy: insights from a large cohort study. Breast Cancer. https://doi.org/10.1007/s12282-024-01663-6

Vancouver

Liu P, Liu D, Zhao C, Wei Y, Liu X, Cui H, et al. Identifying subgroups of ypN1 breast cancer patients who may exempt from axillary lymph node dissection after neoadjuvant chemotherapy: insights from a large cohort study. Breast Cancer. 2025. doi:10.1007/s12282-024-01663-6

BibTeX
@article{Liu2025,
  author = {Liu, Peinan and Liu, Dandan and Zhao, Changying and Wei, Yumeng and Liu, Xingyu and Cui, Hanxiao and Zhao, Xuyan and Chang, Lidan and Lin, Shuai and Wu, Hao and Ma, Xiaobin and Kang, Huafeng and Wang, Meng},
  title = {Identifying subgroups of ypN1 breast cancer patients who may exempt from axillary lymph node dissection after neoadjuvant chemotherapy: insights from a large cohort study},
  journal = {Breast Cancer},
  year = {2025},
  doi = {10.1007/s12282-024-01663-6}
}
Kostenlos starten →